Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Key Points in the Management of Lupus and Lupus Nephritis

Listen to expert insights from Drs Karen Costenbader and Brad Rovin as they discuss key questions from the webinar “Lupus and Lupus Nephritis: Improving Outcomes and Reducing Disparities.”
Karen H. Costenbader, MD, MPH
Brad H. Rovin, MD
Released: June 6, 2022

In this episode, listen as Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, answer key questions about identifying patients at high risk for lupus nephritis, whether an elevated serum creatinine always signals lupus nephritis, the safety of newer therapies for lupus in women who are pregnant or breastfeeding, and the possibility of using SGLT2 inhibitors in patients with lupus nephritis.

Information on this Educational Activity


Karen H. Costenbader, MD, MPH

Professor of Medicine
Department of Medicine
Harvard Medical School
Director, Lupus Program
Division of Rheumatology, Inflammation and Immunity
Brigham and Women's Hospital
Boston, Massachusetts

Karen H. Costenbader, MD, MPH, has disclosed that she has received research funding from Exagen, Gilead Sciences, and Merck and consulting fees from Amgen, AstraZeneca, GlaxoSmithKline, Janssen, and Lilly.
Brad H. Rovin, MD

Professor and Director, Division of Nephrology
The Lee A. Hebert Professor of Nephrology
Medical Director
, The Ohio State Center for Clinical Research Management
The Ohio State University Wexner Medical Center
Columbus, Ohio

Brad H. Rovin, MD, has disclosed that he has received funds for research from Aurinia Pharmaceuticals, Biocryst, Biogen Idec, Bristol-Myers Squibb, Callidatis, Chemocentryx, Human Genome Sciences, Idorsia, and Lucin and consulting fees from Admirx, Alexion, AstraZeneca, Aurinia Pharmaceuticals, Biocryst, Biogen Idec, Bristol-Myers Squibb, Callidatis, Chugai Pharma, Corrona, EMD Serono, Genentech/Hoffman-La Roche, Janssen, Kezar Life Sciences, Lilly, Morphosys, Novartis, Omeros, Otsuka, Pfizer, Principia, and Travere Therapeutics.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This educational activity is supported by an educational grant from

Related Content

Get the latest evidence-based updates on systemic, targeted therapies for the management of moderate to severe atopic dermatitis for patients of all ages!

Robert Sidbury, MD, MPH Jonathan Silverberg, MD Released: December 6, 2022

This downloadable infographic resource from Clinical Care Options (CCO) reviews the therapeutic drug monitoring principles in managing anti-TNF agents in IBD

Bruce E. Sands, MD, MS Released: November 7, 2022

Clinical Care Options (CCO) podcast: Drs Karen Costenbader and Brad Rovin discuss health disparities in lupus and lupus nephritis

Karen H. Costenbader, MD, MPH Brad H. Rovin, MD Released: June 2, 2022

On-demand webcast featuring expert discussion of recent advances in systemic lupus erythematosus (SLE) and lupus nephritis, from Clinical Care Options (CCO)

Karen H. Costenbader, MD, MPH Brad H. Rovin, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Released: May 25, 2022 Expired: May 24, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings